A team from the Spanish National Cancer Research Centre (CNIO) has discovered a novel way in which tumor cells alter the brain to establish themselves and spread cancer. They also demonstrate that a drug that prevents this process already exists and is approved for other indications. The finding is published in the journal ‘Cancer Research’.

An international team led by the ITACA Institute at the Universitat Politècnica de València (UPV) has developed one of the most comprehensive and detailed structural atlases of the human brain to date. Known as HoliAtlas, it will be particularly useful for the study and early diagnosis of neurological and neurodegenerative diseases, such as Alzheimer's or Parkinson's.

The new map is based on ultra-high-resolution multimodal magnetic resonance imaging (MRI) and far exceeds the level of detail found in existing MRI-based atlases.

The study, published in the journal Scientific Reports (Nature), was led by Professor José V. Manjón, coordinator of the MIALAB group at ITACA-UPV, in collaboration with international institutions such as the CNRS and the University of Bordeaux, as well as Spanish and European centres.

A research team from the Department of Pharmacology and Pharmacy, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), has found that nitrogen-containing bisphosphonates (NBPs), a medication widely used in the treatment of osteoporosis, may significantly reduce the risk of Alzheimer’s disease and related dementias (ADRD) in older adults with osteoporosis or fragility fractures. This drug repurposing approach offers a promising avenue for the prevention of ADRD, potentially alleviating the global burden of these conditions. The research findings were published in Alzheimer’s & Dementia.

A St. Jude Children’s Research Hospital–led collaboration created the first large-scale neurodegenerative disease proteome map, a resource for developing new diagnosis tools and treatments.